Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Column Group LLC

Q4 2023 · 13F-HR

Column Group LLCholdings as filed

Filed 2024-02-09 · accession 0000950123-24-001345

$151.4M
Reported value
6
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
75382E109RAPT Therapeutics Inc$66.6M44.0%2,680,621CommonSOLE
68622P109ORICORIC Pharmaceuticals Inc.$32.8M21.7%3,568,181CommonSOLE
87990A106TNYATenaya Therapeutics, Inc.$30.5M20.1%9,400,290CommonSOLE
62921N105NGMUSDNGM Biopharmaceuticals Inc$15.6M10.3%18,136,735CommonSOLE
86889P109Surrozen, Inc.$5.9M3.90%627,651CommonSOLE
76155X100RVMDRevolution Medicines Inc$1,3190.00%46CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.